Evaluation by 18F-FDG-PET of patients with anal squamous cell carcinoma

Hellenic Journal of Nuclear Medicine

Volumn 12, Issue 1, 2009, Pages 26-29

  Iagaru, Andrei ^a   Kundu, Rabi ^b   Jadvar, Hossein ^c   Nagle, Deborah ^b  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b GRADUATE HOSPITAL   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

18F FDG PET; Anal cancer; Squamous cell carcinoma

Indexed keywords

FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; MITOXANTRONE; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADJUVANT CHEMOTHERAPY; ADULT; ANUS CARCINOMA; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER STAGING; CASE STUDY; CLINICAL ARTICLE; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; FEMALE; HUMAN; LYMPH NODE METASTASIS; MALE; POSITRON EMISSION TOMOGRAPHY; RETROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA; TREATMENT RESPONSE; ANUS TUMOR; EVALUATION; METHODOLOGY; MIDDLE AGED; REPRODUCIBILITY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY;

ADULT; ANUS NEOPLASMS; CARCINOMA, SQUAMOUS CELL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY;

EID: 64949089254     PISSN: 11081430     EISSN: 17905427     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71-96.
2. Rabkin CS. Association of non-acquired immunodeficiency syndrome-defining cancers with human immunodeficiency virus infection. J Natl Cancer Inst Monogr 1998; 23: 23-25.
3. Gambhir SS. Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer 2002; 2: 683-693.
4. Trautmann TG, Zuger JH. Positron emission tomography for pre-treatment staging and post-treatment evaluation in cancer of the anal canal. Mol Imaging Biol 2005; 7: 309-313.
5. Cotter SE, Grigsby PW, Siegel BA et al. FDG-PET/CT in the evaluation of anal carcinoma. Int J Radiat Oncol Biol Phys 2006; 65: 720-725.
6. Piperkova E, Raphael B, Altinyay M et al. Impact of PET/CT on initial staging, restaging and treatment management of anal cancer: a clinical case with literature review. J BUON 2006; 11: 523-527.
7. 18F-FDG PET/CT imaging of anal canal squamous cell carcinoma. Clin Nucl Med 2007; 32: 234-236.
8. Nguyen BT, Joon DL, Khoo V et al. Assessing the impact of FDG-PET in the management of anal cancer. Radiother Oncol 2008; 87: 376-382.
9. Sugawara Y, Zasadny KR, Neuhoff AW, Wahl RL. Reevaluation of the standardized uptake value for FDG: variations with body weight and methods for correction. Radiology 1999; 213: 521-525.
10. Clark MA, Hartley A, Ian Geh J. Cancer of the anal canal. Lancet Oncol 2004; 5: 149-157.
11. Kostakoglu L, Goldsmith SJ. PET in the assessment of therapy response in patients with carcinoma of the head and neck and of the esophagus. J Nucl Med 2004; 45: 56-68.
12. Hansen IL, Bruun E. Positron-emission tomography with gamma camera in patients with colorectal and anal cancer. Ugeskr Laeger 1999; 161: 6185-6191.
13. Abrams DI, Kaplan LD, McGrath MS, Volberding PA. AIDS-related benign lymphadenopathy and malignant lymphoma: clinical aspects and virologic interactions. AIDS Res 1986; 2: S131-140.
14. Tatlidil R, Jadvar H, Bading JR, Conti PS. Incidental Colonic Fluorodeoxyglucose Uptake: Correlation with Colonoscopic and Histopathologic Findings. Radiology 2002; 224: 783-787.
15. Schwarz JK, Siegel BA, Dehdashti F et al. Tumor response and survival predicted by post-therapy FDG-PET/CT in anal cancer. Int J Radiat Oncol Biol Phys 2008; 71: 180-186.